Novo Nordisk A/S $NVO Shares Sold by Peapack Gladstone Financial Corp

Peapack Gladstone Financial Corp reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 25.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,091 shares of the company’s stock after selling 25,083 shares during the period. Peapack Gladstone Financial Corp’s holdings in Novo Nordisk A/S were worth $3,719,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in NVO. Clear Harbor Asset Management LLC lifted its stake in Novo Nordisk A/S by 11.3% during the fourth quarter. Clear Harbor Asset Management LLC now owns 4,552 shares of the company’s stock valued at $232,000 after purchasing an additional 462 shares during the last quarter. Sfmg LLC lifted its stake in Novo Nordisk A/S by 5.1% during the fourth quarter. Sfmg LLC now owns 116,017 shares of the company’s stock valued at $5,903,000 after purchasing an additional 5,657 shares during the last quarter. EagleClaw Capital Managment LLC lifted its stake in Novo Nordisk A/S by 0.8% during the fourth quarter. EagleClaw Capital Managment LLC now owns 64,650 shares of the company’s stock valued at $3,289,000 after purchasing an additional 500 shares during the last quarter. Carnegie Lake Advisors LLC lifted its stake in Novo Nordisk A/S by 5.1% during the fourth quarter. Carnegie Lake Advisors LLC now owns 21,175 shares of the company’s stock valued at $1,077,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $25,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its Wegovy pill will launch in the UAE after receiving regulatory approval, another sign that its oral obesity treatment is gaining international traction. Novo Nordisk’s Wegovy Pill to Launch in the UAE Following Regulatory Approval
• Positive Sentiment: Novo Nordisk announced a partnership with NOVI Health in Singapore to expand access to structured weight-care support, which could help broaden adoption of its obesity treatments. NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapore
• Positive Sentiment: Novo Nordisk continued its share repurchase program, a move that can support earnings per share and signal management confidence. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Investors are also watching Novo Nordisk ahead of the ADA conference, where any new diabetes or obesity updates could influence sentiment. Is Novo Nordisk A/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?
• Neutral Sentiment: Analysts are highlighting broader long-term growth potential in GLP-1 drugs, but this is more of a thematic backdrop than a direct catalyst. 5 Best Growth Stocks for the Next 10 Years (NVO)
• Negative Sentiment: Eli Lilly regained CVS Health’s support for GLP-1 access, which may weaken Novo Nordisk’s competitive position in the U.S. obesity-drug market. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage (NVO)
• Negative Sentiment: Tracking data suggests Wegovy’s oral version is still leading Lilly’s rival tablet, but weekly prescription growth is slowing as competition heats up in the GLP-1 space. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows

Novo Nordisk A/S Stock Down 2.6%

NVO stock opened at $42.93 on Wednesday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company’s 50 day simple moving average is $41.12 and its 200-day simple moving average is $46.34. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a market capitalization of $191.70 billion, a P/E ratio of 10.08, a P/E/G ratio of 3.93 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on NVO. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Finally, TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.